Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer

18 Nov 2020

Abstract excerpt

Abstract Purpose: Cisplatin-based chemotherapy is a first-line treatment for muscle-invasive and metastatic urothelial cancer. Approximately 10% of bladder urothelial tumors have a somatic missense mutation in the nucleotide excision repair (NER) gene, ERCC2, which confers increased sensitivity to cisplatin-based chemotherapy. However, a significant subset of patients is ineligible to receive cisplatin-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Cancer Genomics and Diagnostics
Share to DNA Repair Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33208343
DOI: 10.1158/1078-0432.ccr-20-3316

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial CancerPMID 33208343Read ↗

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinomaSemantic proximity Read ↗

Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in CancerSemantic proximity Read ↗

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder CancerSemantic proximity Read ↗

Identification of an <i>ERCC2</i> mutation associated mutational signature of nucleotide excision repair deficiency in targeted panel sequencing dataSemantic proximity Read ↗

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.Semantic proximity Read ↗

Testing the metal of ERCC2 in predicting the response to platinum-based therapy.Semantic proximity Read ↗

Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.Semantic proximity Read ↗

A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor ResistanceSemantic proximity Read ↗

Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung CancerSemantic proximity Read ↗

Bioinformatics analysis of ERCC family in pan-cancer and ERCC2 in bladder cancer.Semantic proximity Read ↗

Doctors revise Declaration of HelsinkiSemantic proximity Read ↗

NPEPPS is a novel and druggable driver of platinum resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.